IBIO

iBio, Inc. is a biotechnology company focused on developing biologics and antibody-based therapeutics using its proprietary FastPharming plant-based manufacturing platform technology. The company's technology platform uses plants to produce complex proteins and antibodies more rapidly and potentially at lower cost than traditional mammalian cell culture methods. iBio has pivoted its focus toward developing its own therapeutic candidates, including programs in oncology and fibrosis, while also offering contract development and manufacturing services. The company's plant-based expression system represents an alternative approach to biologic drug production, though it faces validation and commercialization challenges. iBio operates in the highly competitive and capital-intensive biotechnology sector, where success depends on clinical trial outcomes, regulatory approvals, and manufacturing scalability.